Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Pre-treated Anti-PD-1 Refractory Merkel Cell Carcinoma Successfully Treated with the Combination of PD-1/PD-L1 Axis Inhibitors and TVEC: A Report of Two Cases.

Knackstedt R, Sussman TA, McCahon L, Song JM, Funchain P, Gastman B.

Ann Oncol. 2019 Jun 10. pii: mdz187. doi: 10.1093/annonc/mdz187. [Epub ahead of print] No abstract available.

PMID:
31250007
2.

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.

Ugurel S, Spassova I, Wohlfarth J, Drusio C, Cherouny A, Melior A, Sucker A, Zimmer L, Ritter C, Schadendorf D, Becker JC.

Cancer Immunol Immunother. 2019 Jun;68(6):983-990. doi: 10.1007/s00262-019-02341-9. Epub 2019 Apr 16.

PMID:
30993371
3.

Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma.

Lara KM, In GK, Matcuk GR Jr, Mehta A, Hu JS.

JAAD Case Rep. 2018 Nov 7;4(10):1004-1006. doi: 10.1016/j.jdcr.2018.10.003. eCollection 2018 Nov. No abstract available.

4.

Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma.

von der Grün J, Winkelmann R, Meissner M, Wieland U, Silling S, Martin D, Fokas E, Rödel C, Rödel F, Balermpas P.

Front Oncol. 2019 Jan 24;9:20. doi: 10.3389/fonc.2019.00020. eCollection 2019.

5.

Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.

Bloom BC, Augustyn A, Pezzi TA, Menon H, Mayo LL, Shah SJ, Schwartz DL, Chmura SJ, Johnson FM, Welsh JW, Chun SG.

Front Oncol. 2019 Apr 5;9:223. doi: 10.3389/fonc.2019.00223. eCollection 2019.

6.

Metastatic Merkel cell carcinoma response to nivolumab.

Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD.

J Immunother Cancer. 2016 Nov 15;4:79. eCollection 2016. Erratum in: J Immunother Cancer. 2017 Mar 6;5:27.

7.

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube JM.

Cancer Immunol Res. 2013 Jul;1(1):54-63. doi: 10.1158/2326-6066.CIR-13-0034.

8.

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.

Blackmon JT, Dhawan R, Viator TM, Terry NL, Conry RM.

JAAD Case Rep. 2017 Apr 14;3(3):185-189. doi: 10.1016/j.jdcr.2017.02.003. eCollection 2017 May. No abstract available.

9.

PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.

Mitteldorf C, Berisha A, Tronnier M, Pfaltz MC, Kempf W.

J Cutan Pathol. 2017 Sep;44(9):740-746. doi: 10.1111/cup.12973. Epub 2017 Jun 22.

PMID:
28569410
10.

Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.

Wehkamp U, Stern S, Krüger S, Weichenthal M, Hauschild A, Röcken C, Egberts F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1301-1308. doi: 10.1007/s00432-018-2657-x. Epub 2018 May 9.

PMID:
29744662
11.

PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.

Barkdull S, Brownell I.

Cancer Biol Ther. 2017 Dec 2;18(12):937-939. doi: 10.1080/15384047.2017.1394552. Epub 2017 Nov 27.

12.

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.

Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.

13.

PD-L1 inhibitors in the pipeline: Promise and progress.

Vanella V, Festino L, Strudel M, Simeone E, Grimaldi AM, Ascierto PA.

Oncoimmunology. 2017 Sep 21;7(1):e1365209. doi: 10.1080/2162402X.2017.1365209. eCollection 2017. Review.

14.

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.

Hicks KC, Fantini M, Donahue RN, Schwab A, Knudson KM, Tritsch SR, Jochems C, Clavijo PE, Allen CT, Hodge JW, Tsang KY, Schlom J, Gameiro SR.

Oncoimmunology. 2018 Jul 30;7(11):e1466018. doi: 10.1080/2162402X.2018.1466018. eCollection 2018.

15.

Merkel Cell Carcinoma: An Update and Immunotherapy.

Uchi H.

Front Oncol. 2018 Mar 6;8:48. doi: 10.3389/fonc.2018.00048. eCollection 2018. Review.

16.

Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.

Hirayama Y, Gi M, Yamano S, Tachibana H, Okuno T, Tamada S, Nakatani T, Wanibuchi H.

Cancer Sci. 2016 Dec;107(12):1736-1744. doi: 10.1111/cas.13099. Epub 2016 Dec 13.

17.

PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review.

Choi FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, Linden KG, Shiu J.

J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30881-3. doi: 10.1016/j.jaad.2019.05.077. [Epub ahead of print] Review.

PMID:
31163235
18.

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas.

Mantripragada K, Birnbaum A.

Cureus. 2015 Dec 13;7(12):e403. doi: 10.7759/cureus.403.

19.

Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.

Dilly-Feldis M, Aladjidi N, Refait JK, Parrens M, Ducassou S, Rullier A.

Pediatr Blood Cancer. 2019 May;66(5):e27571. doi: 10.1002/pbc.27571. Epub 2019 Jan 13.

PMID:
30637917
20.

Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.

Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J.

Oncotarget. 2017 Jun 20;8(25):41242-41255. doi: 10.18632/oncotarget.17168.

Supplemental Content

Support Center